Italia markets close in 5 hours 47 minutes

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
66,49+1,49 (+2,30%)
Al 05:34PM GMT. Mercato aperto.

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Settore/i
Settore
Impiegati a tempo pieno292

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Mauro Severino AjaniFounder & Exec. Chairman435,5kN/D1955
Mr. Alessandro E. Della Cha LL.MCEO & Exec. Director659,95kN/D1963
Mr. Ngo Dinh NhanHead of R&D - AI & Biomedical ITN/DN/D1979
Mr. Giulio EvangelistiHead of Production, AI & Biomedical ITN/DN/D1970
Mr. Niall DonnellyChief Financial OfficerN/DN/D1972
Mr. Marco LecchiChief Operating OfficerN/DN/D1964
Mr. Davide MalavasiQualified Person & Technical DirectorN/DN/D1973
Mr. Luigi LongoChief Scientific OfficerN/DN/D1979
Ms. Hazel WinchesterHead of Investor RelationsN/DN/D1971
Mr. Biagio ViganoChief People OfficerN/DN/D1974
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Governance aziendale

L'ISS Governance QualityScore di Cosmo Pharmaceuticals N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.